Ovarian cancer has the highest mortality of all of the gynecological malignancies. There are
several distinct histotypes of this malignancy characterized by specific molecular events and …

Ovarian cancer is the most lethal gynecologic malignancy, and patient prognosis has not
improved significantly over the last several decades. In order to improve therapeutic …

Aim: To demonstrate that exosomes (exo) could increase the therapeutic index of
doxorubicin (DOX). Materials & methods: Exosomes were characterized by nanoparticle …

Triple-negative breast cancers (TNBCs) are characterized by a poor prognosis and lack of
targeted treatments, and thus, new therapeutic strategies are urgently needed. Inhibitors …

Immune therapies have had limited efficacy in high-grade serous ovarian cancer (HGSC), as
the cellular targets and mechanism (s) of action of these agents in HGSC are unknown. Here …

High-grade serous ovarian cancer (HG-SOC)—often referred to as a “silent killer”—is the
most lethal gynecological malignancy. The fallopian tube (murine oviduct) and ovarian …

Ovarian cancer is one of the most common malignant tumours of female reproductive organs
in the world. The pelvic CT scan is a common examination method used for the screening of …

Estrogenic hormone replacement therapy increases the risk of developing ovarian cancer,
and estrogen promotes tumour initiation and growth in mouse models of this disease …

High‐grade serous carcinoma (HGSC) is the most common and malignant histological type
of epithelial ovarian cancer, the origin of which remains controversial. Currently, the …

The lack of significant progress in treating epithelial ovarian cancer (EOC) underscores the
need to gain a 15 better understanding of the processes that lead to chemoresistance and …